BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals, Inc. today announced the addition of two members to its Scientific Advisory Board. Wayne William Hancock, MD, PhD, Professor of Pathology and Laboratory Medicine and Chief, Division of Transplantation Immunology at Children’s Hospital of Pennsylvania, and Tso-Pang Yao, PhD, Associate Professor of Pharmacology and Cancer Biology and Associate Professor of Radiation Oncology at Duke University Medical Center, join Acetylon’s Scientific Advisory Board as the Company is advancing its lead drug candidate, ACY-1215, a selective inhibitor of histone deacetylase-6 (HDAC6), into human clinical trials. The first indications targeted for Acetylon’s next-generation small molecule HDAC inhibitors are multiple myeloma and inflammatory disorders, such as rheumatoid arthritis.
